DiscoveryProbe™ FDA-approved Drug Library: GPCR Targeting In
2026-08-03
Discover how the DiscoveryProbe FDA-approved Drug Library enables innovative GPCR ligand discovery and pharmacological target identification. This article uniquely explores the intersection of structure-based screening and drug repositioning, offering fresh insights for translational research.
Phalloidin (B7678): Technical Guidance for Actin Cytoskeleto
2026-08-03
Phalloidin (SKU B7678) is a cyclic heptapeptide toxin used for high-affinity stabilization and visualization of filamentous actin (F-actin) in fixed or permeabilized samples. It is optimal for static cytoskeleton analysis and microscopy-based workflows but is not suitable for live-cell imaging or studies requiring reversible actin interactions.
Phebestin: A Potent Aminopeptidase Inhibitor Against Malaria
2026-08-02
The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a highly effective compound with nanomolar inhibitory activity against both chloroquine-sensitive and -resistant Plasmodium falciparum strains. These findings highlight phebestin’s potential in overcoming malaria drug resistance and inform future antimalarial drug development strategies.
Deferiprone in Iron Stress Research: Protocols and Solutions
2026-08-01
Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is transforming iron stress research by enabling precise modulation of cellular iron and dissecting iron-dependent metabolic pathways. This article unpacks stepwise workflows, troubleshooting insight, and advanced applications in cancer and enterocyte models—anchored by the latest metabolomic evidence.
Cl-Amidine (trifluoroacetate salt): Reliable PAD4 Inhibition
2026-07-31
This article provides scenario-driven guidance for leveraging Cl-Amidine (trifluoroacetate salt) (SKU C3829) in cell viability, proliferation, and cytotoxicity workflows. It addresses common experimental pain points and demonstrates how this selective PAD4 inhibitor from APExBIO delivers reproducible, data-backed performance in both in vitro and in vivo research.
iPSC-Based Clinical Trial Selection for Ultrarare Disease Th
2026-07-31
This study introduces a patient-specific iPSC platform to prescreen drug efficacy for ultrarare, previously uncharacterized mutations in Leigh-like syndrome. The approach allows for tailored evaluation of therapeutic candidates, potentially improving patient outcomes and refining trial selection in rare metabolic disorders.
1,2-Dioleoyl-sn-glycero-3-PE (DOPE): Beyond Delivery—A Lipid
2026-07-30
Explore how 1,2-Dioleoyl-sn-glycero-3-PE (DOPE) advances nucleic acid delivery and offers new insight into ferroptotic cell death mechanisms. This article provides a lipidomics-driven analysis that sets DOPE apart as more than a standard helper lipid.
CARMIL MB Domain: Mechanisms Regulating Actin Capping Protei
2026-07-30
The reference study reveals how the membrane-binding (MB) domain of CARMIL orchestrates the targeting, activation, and release of actin capping protein (CP) at cellular membranes. These findings clarify how localized regulation of CP enables precise actin assembly, with implications for dissecting membrane-protein interactions in cytoskeletal research.
Phytol in RXR Signaling: Applied Workflows & Optimization Gu
2026-07-29
Phytol (trans-Phytol) delivers flexible, reliable RXR activation for both cell-based signaling studies and advanced nanomaterial assays. This article details protocol enhancements, troubleshooting strategies, and actionable insights drawn from benchmark studies, positioning APExBIO's Phytol as a cornerstone for nuclear receptor and self-assembly research.
SNS-032 (BMS-387032): Bridging Cancer and Antiviral Innovati
2026-07-29
Explore how SNS-032 (BMS-387032) is reshaping translational research at the intersection of cancer therapy and host-targeted antiviral strategies. This thought-leadership article unpacks the compound’s mechanistic impact on cyclin-dependent kinases, illuminates new protocol guidance, and evaluates the implications of RNA Pol II phosphorylation modulation in disease models. Drawing on both foundational oncology data and pioneering host-pathogen findings, the discussion spotlights workflow design, limitations, and the rationale for expanded cross-domain applications.
Isolation of HLA-G+ Trophoblasts: Protocols for Maternal-Fet
2026-07-28
Hamilton et al. present a detailed protocol for isolating and culturing primary HLA-G+ extravillous trophoblasts (EVTs) and EVT-like cell lines from human placental tissues. This methodological advance enables rigorous study of maternal-fetal immune interactions and supports the development of functional co-culture assays using highly viable EVT populations.
Suhuang Capsule Inhibits ER Stress–NLRP3 Axis in Cough Varia
2026-07-28
This study demonstrates that Suhuang antitussive capsule ameliorates pulmonary dysfunction in cough variant asthma by suppressing endoplasmic reticulum (ER) stress and inhibiting NLRP3 inflammasome activation. These findings clarify the mechanistic link between ER stress, mitochondrial dynamics, and airway inflammation, informing future research on targeted interventions.
Chlorpromazine in Hepatic Nanomedicine: Beyond Antipsychotic
2026-07-27
Explore how chlorpromazine advances antipsychotic research and provides unique insight into hepatic nanoparticle interactions. This in-depth article reveals novel applications of chlorpromazine, including its role as a pharmacological probe in nanomedicine and liver cell targeting.
Targeting Glutamine Metabolism in HSCs to Alleviate Liver Fi
2026-07-27
This study demonstrates that inhibiting glutamine metabolism in hepatic stellate cells (HSCs) effectively reduces liver fibrosis, highlighting the regulatory role of SIRT4 in this process. The work provides mechanistic insights and suggests new metabolic targets for fibrotic disease intervention.
Mutational Profiling in Myeloma Cell Lines: Drivers and Drug
2026-07-26
This study delivers the first comprehensive exome-wide analysis of 30 human multiple myeloma cell lines, mapping key mutational drivers and pathways linked to disease progression and drug resistance. The results provide foundational resources for experimental model selection and highlight novel candidate genes relevant for hematological malignancy research.
508 records 13/34 page Previous Next First page 上5页 1112131415 下5页 Last page